InteRNA Technologies Announces Establishment of Scientific Advisory Board
Technologies B.V., a biopharmaceutical company focusing on the development of
intelligent microRNA (miRNA)-based therapeutics for cancer, announces the
establishment of its Scientific Advisory Board (SAB). The SAB will further
guide the Company in the development of cancer therapies based on the unique
functions of its proprietary miRNAs.
The SAB is chaired by
Oncology at the Department of Medical Oncology, UMC
Other distinguished members are: - Jaap Verweij, MD, PhD, Professor of Medical Oncology at the Department. of Medical Oncology at Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; - William C. Hahn, MD, PhD, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute and Senior Associate Member at the Broad Institute of Harvard and MIT, Boston, USA; - Allan Balmain, PhD, FRSE, Barbara Bass Bakar Distinguished Professor in Cancer Genetics at UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA; - Graham Dixon, PhD, Sr. VP Drug Discovery, Galapagos NV, Mechelen, Belgium; - Edwin Cuppen, PhD, scientific co-founder of InteRNA Technologies, and Professor of Genome Biology at Utrecht University, Professor of Human Genetics and head of the Research section of the Department of Medical Genetics, UMC Utrecht and staff scientist at Hubrecht Institute, Utrecht, the Netherlands; - Eugene Berezikov, PhD, scientific co-founder of InteRNA Technologies and staff scientist at Hubrecht Institute, the Netherlands.
“We are very pleased with the formation of our SAB and feel honored to
collaborate with this experienced team that is highly committed advising the
Company on moving forward its research and development towards the clinic”,
knowledge of the renowned clinicians and scientists in this team will play a
significant role in our R&D programs and success of the Company.”
“While fundamental research has now unequivocally demonstrated the importance
of miRNA’s in regulation and deregulation of biological processes, InteRNA
Technologies has in the past few years build up a unique position in
converting this knowledge into miRNA-based cancer treatment strategies. These
activities are now further supported by a wealth of knowledge and expertise
through this SAB, which will undoubtedly further accelerate the path towards
About InteRNA Technologies B.V.
InteRNA Technologies B.V. actively explores and exploits opportunities to
translate its unique collection of miRNAs and miRNA discovery and validation
technologies into successful diagnostic, prognostic and therapeutic
applications. The company’s primary focus is to unravel the role of its
proprietary miRNAs in cancer.
InteRNA Technologies was incorporated in 2006 by Aglaia Oncology Fund and
has established close relationships with the research groups of its founders
See for more information http://www.interna-technologies.com.
SOURCE InteRNA Technologies B.V.